CGEN COM701 in combination with nivolumab ± BMS-986207 (anti-TIGIT) in heavily pretreated patient population, resulted in encouraging durable confirmed partial responses (overall response rate 20% (n=20) triple study, 10% (n=20) dual study and disease control rate (45%) for both), supported by immune activation with a favorable safety and toxicity profile Three of the patients responded to triplet therapy for at least 9 months as of the data cut-off date and all four triplet responders continue treatment Anti-tumor activity with confirmed partial responses reported in diverse histologies, with majority (5 out of 6 responders in the two combinations) in the hardest to treat high-grade serous adenocarcinoma histology which is typically less responsive to immune checkpoint inhibitors

BDTX Black Diamond Therapeutics Inc. is cutting one of its cancer programs and laying off an undisclosed number of employees.